Palobiofarma 
Welcome,         Profile    Billing    Logout  
 6 Products   1 Disease  6 Products   4 Trials   119 News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PBF-680 / Palobiofarma
2021-001732-25: A clinical trial to assess the effect of PBF-680 in patients with moderate to severe Chronic Obstructive Pulmonar Disease on top of standard medication. Ensayo clínico para evaluar el efecto del PBF-680 en pacientes con Enfermedad Pulmonar Obstructiva Crónica de moderada a severa, conjuntamente con la medicación habitual.

Ongoing
2
102
Europe
PBF-680, Capsule, hard
Palobiofarma, S.L, Palobiofarma, S.L
Patients with moderate to severe Chronic Obstructive Pulmonar Disease (COPD) Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a grave., Patients with moderate to severe Chronic Obstructive Pulmonar Disease (COPD) Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) de moderada a grave., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Respire, NCT05262218: Therapeutic Effect of PBF-680 in Patients With COPD

Completed
2
174
Europe
PBF-680 10mg, Placebo
Palobiofarma SL, Scope International AG
COPD
02/24
04/24
taminadenant (NIR178) / Novartis
CNIR178X2201, NCT03207867 / 2017-000241-49: A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Terminated
2
315
Europe, Japan, US, RoW
NIR178, taminadenant, PDR001, spartalizumab
Novartis Pharmaceuticals
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
02/23
02/23
NCT03742349: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Terminated
1
64
Europe, Japan, US, RoW
spartalizumab, PDR001, LAG525, NIR178, capmatinib, INC280, MCS110, canakinumab, ACZ885
Novartis Pharmaceuticals
Triple Negative Breast Cancer (TNBC)
02/23
02/23
NCT04237649: KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Terminated
1
77
Europe, Canada, Japan, US, RoW
KAZ954, PDR001, NIR178, NZV930
Novartis Pharmaceuticals
Solid Tumors
09/23
09/23
CDFF332A12101, NCT04895748 / 2020-004383-25: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Active, not recruiting
1
40
Europe, Japan, US, RoW
DFF332, RAD001, Everolimus, PDR001, Spartalizumab, NIR178, Taminadenant
Novartis Pharmaceuticals
Carcinoma, Renal Cell
09/25
09/25
PBF-1129 / Palobiofarma
NCT03274479: PBF-1129 in Patients With NSCLC

Active, not recruiting
1
18
US
PBF-1129
Palobiofarma SL, Ohio State University
Locally Advanced or Metastatic NSCLC
05/24
08/24
NCT05234307: PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Recruiting
1
30
US
Adenosine A2B Receptor Antagonist PBF-1129, A2BR Antagonist PBF-1129, PBF 1129, PBF-1129, PBF1129, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
Dwight Owen, National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/24
12/25
PBF-1650 / Palobiofarma
No trials found
Undisclosed CD73 inhibitor / Palobiofarma
No trials found
PBF-999 / Palobiofarma
No trials found
PBF-677 / Palobiofarma
No trials found
PBF-2828 / Palobiofarma
No trials found

Download Options